Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 12:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–11 of 11 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Kentuckiana Cancer Institute Clear all
Completed No phase listed Observational Accepts healthy volunteers

Genetic Epidemiology of Adult Onset Glioma

NCT00283569
View directory record Official record
Conditions
Adult-Onset Glioma
Interventions
Mouth Swab, Toe Nail Clippings, Questionnaires
Other
Lead sponsor
Kentuckiana Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2010
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jan 20, 2010 · Synced Oct 4, 2026, 12:35 PM EDT
Completed Not applicable Interventional Results available

Combined Immunochemotherapy Followed By Reduced Dose Radiation Therapy (RT) for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma

NCT00594815
View directory record Official record
Conditions
Lymphoma
Interventions
Cytarabine, Leucovorin, Methotrexate, Procarbazine, Rituximab, Vincristine
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 6, 2017 · Synced Oct 4, 2026, 12:35 PM EDT
Completed Phase 2 Interventional

Phase II Trial of ZD1839 (Iressa) in Patients With Nonresectable Adrenocortical Carcinoma (ACC)

NCT00215202
View directory record Official record
Conditions
Nonresectable Adrenocortical Carcinoma
Interventions
Iressa (ZD1839)
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
4
States / cities
Louisville, Kentucky • Boston, Massachusetts • Lebanon, New Hampshire + 1 more
Source: ClinicalTrials.gov public record
Updated May 17, 2018 · Synced Oct 4, 2026, 12:35 PM EDT
Completed Not applicable Interventional

Iscar for Second Line Treatment of Advanced Non-Small Cell Lung Cancer

NCT00283478
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Iscar Quercus, Gemcitabine
Drug
Lead sponsor
Kentuckiana Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 31, 2007 · Synced Oct 4, 2026, 12:35 PM EDT
Not listed Phase 2 Interventional

A Phase II Study of Gliadel, Concomitant Temozolomide and Radiation, Followed By Dose Dense Therapy With Temozolomide For Newly Diagnosed Malignant High Grade Glioma

NCT00660283
View directory record Official record
Conditions
Glioma
Interventions
Temozolomide
Drug
Lead sponsor
Kentuckiana Cancer Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jan 20, 2010 · Synced Oct 4, 2026, 12:35 PM EDT
Not listed Phase 2 Interventional

A Phase II Study Of Gliadel, Concomitant Temozolomide And Radiation, Followed By Dose Dense Therapy With Temozolomide Plus Bevacizumab For Newly Diagnosed Malignant High Grade Glioma

NCT00660621
View directory record Official record
Conditions
Glioma
Interventions
Temozolomide and Bevacizumab
Drug
Lead sponsor
Kentuckiana Cancer Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jan 20, 2010 · Synced Oct 4, 2026, 12:35 PM EDT
Not listed Phase 2 Interventional

Radiation With Concomitant and Then Sequential Temozolomide in Malignant Glioma

NCT00283543
View directory record Official record
Conditions
Newly Diagnosed Supratentorial Malignant Glioma
Interventions
Gliadel Wafer, Temozolomide, Limited field radiation
Drug · Procedure
Lead sponsor
Kentuckiana Cancer Institute
Other
Eligibility
18 Years to 72 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 31, 2007 · Synced Oct 4, 2026, 12:35 PM EDT
Completed Phase 1Phase 2 Interventional

High Dose Camptothecin-11 (CPT-11) in Recurrent Unresectable Malignant Glioma

NCT00283556
View directory record Official record
Conditions
Malignant Glioma
Interventions
Irinotecan (Camptosar, CPT-11)
Drug
Lead sponsor
Kentuckiana Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jan 20, 2010 · Synced Oct 4, 2026, 12:35 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Risk Factors for Adult-Onset Brain Tumors

NCT00592865
View directory record Official record
Conditions
Brain Neoplasm, Primary, Brain Neoplasms, Malignant, Brain Neoplasms, Benign
Interventions
Not listed
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
850 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2015
U.S. locations
5
States / cities
Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Oct 4, 2026, 12:35 PM EDT
Terminated Phase 1Phase 2 Interventional

Docetaxel, Irinotecan, and Carboplatin in Extensive Stage Non-Small Cell Lung Cancer

NCT00264134
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Extensive Stage Unresectable
Interventions
Docetaxel, Irinotecan, Carboplatin
Drug
Lead sponsor
Kentuckiana Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jan 20, 2010 · Synced Oct 4, 2026, 12:35 PM EDT
Terminated No phase listed Observational

Tumor Phenotypes and Correlation to Clinical Outcomes in Cancer

NCT00283530
View directory record Official record
Conditions
Cancer
Interventions
Tumor biopsy
Procedure
Lead sponsor
Kentuckiana Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jan 20, 2010 · Synced Oct 4, 2026, 12:35 PM EDT